Originally published as JCO Early Release 10.1200/JCO.2007.10.9777 on June 18 2007

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Carver, J. R. Search for Related Content PubMed PubMed Citation Articles by Carver, J. R. Related Articles Related Editorial Related Correspondence

American Society of Clinical Oncology Clinical Evidence Review on the Ongoing Care of Adult Cancer Survivors: Cardiac and Pulmonary Late Effects

Joseph R. Carver, Charles L. Shapiro, Andrea Ng, Linda Jacobs, Cindy Schwartz, Katherine S. Virgo, Karen L. Hagerty, Mark R. Somerfield, David J. Vaughn for the ASCO Cancer Survivorship Expert Panel

From the Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA; Ohio State University Comprehensive Cancer Center, Columbus, OH; Brigham and Women's Hospital, Boston, MA; Brown University, Providence, RI; St Louis University Medical Center & Department of Veterans Affairs Medical Center, St Louis, MO; and the American Society of Clinical Oncology, Alexandria, VA

Address reprint requests to the American Society of Clinical Oncology, Cancer Policy and Clinical Affairs, 1900 Duke St, Suite 200, Alexandria, VA 22314; e-mail: guidelines{at}asco.org

Purpose: To review the evidence on the incidence of long-term cardiac or pulmonary toxicity secondary to chemotherapy, radiotherapy, or trastuzumab in symptomatic and asymptomatic cancer survivors.

Methods: An American Society of Clinical Oncology Panel reviewed pertinent information from the literature through February 2006.

Results: Few studies directly addressing the benefits of screening for long-term cardiac or pulmonary toxicity in asymptomatic cancer survivors who received chemotherapy, radiotherapy, or trastuzumab were identified. The reviewed literature included primarily retrospective and cross-sectional studies describing the incidence of cardiac and pulmonary late effects. Anatomic and/or functional abnormalities have been associated with use of all currently available anthracyclines and their derivatives. Trastuzumab-related cardiac dysfunction rarely causes death, and in most cases is reversible with improvement in cardiac function on drug discontinuation and/or treatment with cardiac medications. The estimated aggregate incidence of radiation-induced cardiac disease is 10% to 30% by 5 to 10 years post-treatment, although the incidence may be lower with modern techniques. Radiation pneumonitis is reported in 5% to 15% of lung cancer patients receiving definitive external-beam radiation therapy. A minority of patients may develop progressive pulmonary fibrosis; late complications include cor pulmonale and respiratory failure. Bleomycin-induced pneumonitis is an acute rather than late effect of treatment. Late pulmonary complications in bone marrow or stem cell transplantation patients who develop interstitial pneumonitis include idiopathic pneumonia syndrome and bronchiolitis obliterans.

Conclusion: An increased incidence of cardiac and/or pulmonary dysfunction is observed in cancer survivors. Research is needed to identify high-risk patients, and to determine the optimal screening strategies and subsequent treatment.

published online ahead of print at www.jco.org on June 18, 2007.

J.R.C., C.L.S., A.N., and D.J.V. are members of the writing committee.

C.L.S. and D.J.V. are co-chairs of the American Society of Clinical Oncology Cancer Survivorship Expert Panel.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

Related Editorial

• Cancer Survivorship Research and Guidelines: Maybe the Cart Should Be Beside the Horse
  Craig C. Earle
  JCO 2007 25: 3800-3801 [Full Text]

Related Correspondence

• Clinical Management of Long-Term Cancer Survivors
  Cecilia Simonelli, Massimiliano Berretta, Umberto Tirelli, and Maria A. Annunziata
  JCO 2008 26: 161-162 [Full Text]

This article has been cited by other articles:

				J. R. Carver, S. J. Schuster, and J. H. Glick Doxorubicin Cardiotoxicity in the Elderly: Old Drugs and New Opportunities J. Clin. Oncol., July 1, 2008; 26(19): 3122 - 3124. [Full Text] [PDF]

				C. Simonelli, M. A. Annunziata, E. Chimienti, M. Berretta, and U. Tirelli Cancer survivorship: a challenge for the European oncologists Ann. Onc., July 1, 2008; 19(7): 1216 - 1217. [Full Text] [PDF]

				S. E Lipshultz, J. A Alvarez, and R. E Scully Anthracycline associated cardiotoxicity in survivors of childhood cancer Heart, April 1, 2008; 94(4): 525 - 533. [Full Text] [PDF]

				S. Pant, M. B. Landon, M. Blumenfeld, W. Farrar, and C. L. Shapiro Treatment of Breast Cancer With Trastuzumab During Pregnancy J. Clin. Oncol., March 20, 2008; 26(9): 1567 - 1569. [Full Text] [PDF]

				P. A. Ganz, M. A. Hussey, C. M. Moinpour, J. M. Unger, L. F. Hutchins, S. R. Dakhil, J. K. Giguere, J. W. Goodwin, S. Martino, and K. S. Albain Late Cardiac Effects of Adjuvant Chemotherapy in Breast Cancer Survivors Treated on Southwest Oncology Group Protocol S8897 J. Clin. Oncol., March 10, 2008; 26(8): 1223 - 1230. [Abstract] [Full Text] [PDF]

				C. Simonelli, M. Berretta, U. Tirelli, and M. A. Annunziata Clinical Management of Long-Term Cancer Survivors J. Clin. Oncol., January 1, 2008; 26(1): 161 - 162. [Full Text] [PDF]

				C. K. Haston, M. Begin, G. Dorion, and S. M. Cory Distinct Loci Influence Radiation-Induced Alveolitis from Fibrosing Alveolitis in the Mouse Cancer Res., November 15, 2007; 67(22): 10796 - 10803. [Abstract] [Full Text] [PDF]

				C. C. Earle Cancer Survivorship Research and Guidelines: Maybe the Cart Should Be Beside the Horse J. Clin. Oncol., September 1, 2007; 25(25): 3800 - 3801. [Full Text] [PDF]